, et al.. Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD. Pulmonary Pharmacology Therapeutics, 2009Therapeutics, , 22 (3), pp.177. 10.1016Therapeutics, /j.pupt.2008 Please cite this article as: Cazzola M, Santus P, D'Adda A, Pizzolato S, Di Marco F, Centanni S. Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropiuminduced bronchodilation in patients with stable COPD, Pulmonary Pharmacology & Therapeutics (2008), doi: 10.1016/j.pupt.2008 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
T P I R C S U N A M D E T P E C C AT P I R C S U N A M D E T P E C C A
ARTICLE IN PRESS

Abstract
Knowledge on the effects of the additive bronchodilatory effects of short-acting agents on the top of the effect of long-acting bronchodilators is limited. In this trial, we examined the influence of higher than conventional doses of the shortacting inhaled β2-adrenergic agent salbutamol and the short-acting anticholinergic drug ipratropium bromide on bronchodilation induced by a regular treatment with the long-acting anticholinergic drug tiotropium 18 μg/day in 30 patients with stable COPD. On 3 separate days, a dose-response curve to inhaled salbutamol (100 μg puff-1), ipratropium bromide (20 μg puff-1) or placebo was constructed 3 hours after inhalation of last dose of tiotropium, using one puff, one puff, two puffs and two puffs, for a total cumulative dose of 600 μg salbutamol or 120 μg ipratropium bromide. Doses were given at 30-min intervals and Both drugs did not affect heart rate and SpO2. Our results indicate that there is not much difference in bronchodilation between adding higher than conventional doses of salbutamol or ipratropium bromide to tiotropium in patients with stable COPD. Effective improvement of the pulmonary function may be achieved in such a type of patients by adding salbutamol 600 μg or ipratropium bromide 120 μg to regular tiotropium. These is an interesting finding mainly for those COPD patients suffering from cardiovascular co-morbidities that are at highest risk of myocardial infarction, congestive heart failure, cardiac arrest and sudden cardiac death when treated with elevated doses of a ß2-agonist. (EudraCT number: 2007-001597-82)
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Introduction
National and international guidelines [1] [2] [3] suggest that long-acting bronchodilator therapy should always be considered when patients with COPD are symptomatic, but no distinction is made as to which class of drugs should be considered first, although anticholinergics agents are of noteworthy value since parasympathetic cholinergic pathways arising from the vagus nerve are implicated in the pathophysiology of airflow obstruction in COPD [4] [5] [6] . The most recently approved maintenance therapy for the treatment of stable COPD is the once-daily anticholinergic tiotropium. A systematic review has documented that this agent improves lung function, reduces lung hyperinflation, improves exercise endurance time, reduces COPD exacerbations and related hospitalisations, and improves quality of life and symptoms [7] . It has been suggested s likely that tiotropium might also influence the decline in forced expiratory volume in one second (FEV 1 ), but a 4-year trial of tiotropium in COPD was associated with improvements in lung function, quality of life, and exacerbations during a 4-year period but did not significantly reduce the rate of decline in FEV 1 [8] . An additional benefit of tiotropium is a reduction in the need for relief medication to control breakthrough symptoms, although relief medication is still normally required on a daily basis in many COPD patients [9] [10] [11] [12] .
Short-acting inhaled bronchodilators (β 2 -agonists and anticholinergics) are generally reserved for as required use because they bring quick relief for breathlessness. They can also be used to prevent or reduce symptoms that are known to be caused by specific situations such as exercise. It has been documented that the acute addition of a standard dose of ipratropium to long acting β 2 -agonists, salmeterol [13] or formoterol [14] in their usual dosages, does not appear to improve pulmonary function, but higher than normal doses of an anticholinergic drug are able to induce further relief of bronchospasm in patients with COPD when an inhaled dose of a long-acting β 2 -agonist is given first [15] . It has also been recognized that pre-treatment with a conventional dose of
a long-acting β 2 -agonist does not preclude the possibility of inducing a further bronchodilation with higher that the customary dose of salbutamol in patients suffering from COPD [16] .
In contrast, although there is good evidence that adding a normal dose of a long-acting β 2 -agonist to tiotropium is effective [17, 18] This is interesting information, but in our opinion the real therapeutic potential of this addition can only be established using doses higher than those currently recommended in the marketing of these agents. We believe that when the response to bronchodilators is tested, a dose-response assessment should be undertaken, mainly in severe COPD. In fact, in patients classified as COPD, there is clearly a wide variation of response to bronchodilators and a surprising degree of reversibility can be achieved. Due to this variation in response, conventional drug doses may often be too small [20] . This is a crucial point when we are considering useful to add a short-acting bronchodilator as a rescue medication.
Therefore, we have examined the possible acute effects of higher than standard doses of a short-acting β 2 -agonist, salbutamol, and a short-acting anticholinergic agent, ipratropium, on tiotropium-induced bronchodilation in patients with stable COPD.
Patients and Methods
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Thirty outpatients with moderate to severe COPD but in a stable phase of the disease were assessed. All were >50 years of age, current or former smokers (>10 pack years) without a history of asthmatic attacks, reporting chronic cough with or without sputum production and/or dyspnoea when walking quietly on level ground, or both; they had had no change in symptom severity or treatment in the preceding four weeks, had shown no signs of a respiratory tract infection in the month preceding or during the trial, had not been taking oral or inhaled corticosteroids for at least three months, and had a FEV 1 All patients, who were under regular treatment with tiotropium 18 μg/die from at least 6 months, received the daily dose of tiotropium. Functional testing was performed immediately before inhalation of treatment and after three hours.
FEV 1 , inspiratory capacity (IC), and FVC were assessed. The patients were investigated in the morning in a sitting position. IC was determined by a slow manoeuvre (slow inspiration until maximum volume after regular tidal breathing), while functional residual capacity (FRC) was determined by asking patients to pant at a frequency of 51 Hz against a closed shutter. This manoeuvre was followed by a slow manoeuvre to obtain total lung capacity (TLC) and residual volume (RV). Specific airway resistance (sRaw) and thoracic gas volume (TGV)
were measured using a constant volume variable pressure body plethysmograph at each visit.
Three hours after the inhalation of tiotropium, a dose-response curve to inhaled salbutamol (100 µg/puff), ipratropium bromide (20 µg/puff) or placebo was constructed using one puff, one puff, two puffs, and two puffs -that is, a total cumulative dose of 600 µg salbutamol or 120 µg ipratropium bromide.
Salbutamol, ipratropium bromide or placebo were administered from an MDI and holding chamber (AeroChamber) with a mouthpiece. Dose increments were given at 30 minute intervals with measurements being made 15 minutes after each dose. On three non-consecutive days all patients received one of the following:
(1) 18 µg tiotropium + 600 µg salbutamol, (2) 18 µg tiotropium + 120 µg ipratropium bromide, or (3) 18 µg tiotropium + placebo.
The FEV 1 improvement induced by 600 µg salbutamol, 120 µg ipratropium or placebo (six puffs) over tiotropium was chosen as the primary outcome variable. With an estimation of the within subject variability (residual standard deviation) of 0.10 L, this crossover study with 30 patients had 80% power to detect a difference of at least 0.08 L between treatments. Analysis of spirometric data for each treatment was performed using the Student's t test for paired variables. Mean responses were also compared by multifactorial analysis of variance (ANOVA) to establish any significant overall effect between all treatments. In the presence of a significant overall ANOVA, Duncan's multiple range testing with 95% confidence limits (CI) was used to identify where differences were significant. A probability level of p<0.05 was considered significant for all tests.
Results
All patients completed the three day study. There were no significant differences between the baseline spirometric values of the three treatment groups (FEV 1 , p =
Moreover, tiotropium always induced a significant (p<0.0001) increase in all the explored parameters three hours after its inhalation (Table 2 ).
In the dose-response curve (figure 1) both salbutamol and ipratropium but not placebo elicited an evident increase in FEV 1 . Specifically, the further mean maximum increase induced by 600 µg salbutamol or 120 µg ipratropium (table 3) was 0.157 L (95% CI of differences 0.108 to 0.206) and 0.125 L (95% CI of differences 0.068 to 0.182), respectively, whereas that elicited by placebo was All drugs did not affect heart rate and SpO 2 ( Table 2 and 3) . Moreover, no patient complained of adverse symptoms, such as dry mouth and noted tremor, or reported any difference in the taste of the inhalers. Our results fit well with the documentation that add-on therapy of the longacting β 2 -agonist formoterol to tiotropium maintenance therapy significantly improved spirometric variables, including IC [18] . We cannot exclude that the larger bronchodilatory response that we observed when a short-acting bronchodilator was given after tiotropium should be justified by a carry over effect, considering that tiotropium is a long-lasting bronchodilator. Nonetheless, it is well know that the mean peak bronchodilation with tiotropium in COPD patients is reached after 3 h [31], and in the present study we have documented that the administration of a second bronchodilator added 3 h after the inhalation of tiotropium could amplify its maximum bronchodilation. This finding seems to be important because it indicates the possibility that a patient who is under regular tiotropium and is unable to perceive bronchodilation or must perform an exercise could use a high dose of a short-acting bronchodilator as reliever medication when needed. 
